News Listing

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, to develop and commercialize transplant monitoring products using Bio-Rad’s Droplet Digital™ PCR (ddPCR™) instruments and reagents.

Search Highlights

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Each TMA features multiple normal tissue ...

HERCULES, Calif., and PITTSBURGH, Penn. — April 8, 2024 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader of life science research and clinical diagnostics products, today announces a collaboration with Allegheny Health Network (AHN), a western Pennsylvania–based integrated healthcare system. This research collaboration aims to generate clinical evidence across a range of cancer ...

HERCULES, Calif. — April 02, 2024 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.b), a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. The assay expands the company’s Droplet Digital PCR (ddPCR™) offering for the oncology market, where highly ...

Antibodies Validated for Use with Bio-Rad’s Celselect Slides™ Enumeration Stain Kits to Enable Immunostaining of Captured Circulating Tumor Cells in Liquid Biopsy Samples.

Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced the winners of its second Innovation & Entrepreneurship Awards.

THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE ...

Produced using a patented dry-spinning technology - CollaFibR™ from AMSBIO is a highly consistent collagen fibre matrix that closely mimics the biomechanical and biochemical properties of natural collagen scaffolds, offering a highly accurate representation of in-vivo conditions.
These innovative collagen fibres are seamlessly produced on a commercial scale using an automated state-of-the-art ...